The White House’s MAHA Gatekeeper

The inner workings of the White House have long been shrouded in secrecy, but a recent battle over psychedelic therapies has shed light on the quiet influence of Dr. Heidi Overton, a mid-level health adviser on the Domestic Policy Council. As the gatekeeper for President Trump’s “Make America Healthy Again” (MAHA) initiative, she has become a target for criticism within MAHA circles.

Overton’s detractors paint her as a roadblock to radical change. They accuse her of slow-walking marijuana rescheduling, diluting initiatives like childhood-vaccine recommendations and food pyramid redesign, and even undermining Trump’s own desires. This portrayal has sparked a heated debate within the White House and among MAHA supporters.

As a senior health-policy official on the Domestic Policy Council, Overton’s task is to translate the president’s priorities into concrete policy documents that advance the administration’s agenda. In theory, this should be a straightforward process. However, in reality, Overton has become embroiled in a web of conflicting interests and competing factions.

The recent controversy over psychedelic therapies is just one example of how Overton’s influence has been felt. When Joe Rogan reached out to Trump about the healing potential of ibogaine, the president seemed receptive, even enthusiastic. However, as the drafting process unfolded, Overton’s team intervened, significantly scaling back the original policy document and removing key provisions. This led to a tense standoff between Rogan’s allies and Overton.

The White House has rushed to Overton’s defense, describing her as a “star scientific wonk” who knows how to balance competing interests to achieve the president’s objectives. Press Secretary Karoline Leavitt even stated that Trump “adores” her. However, this portrayal raises questions about why she has become such a target for MAHA supporters.

Overton’s long tenure on the Domestic Policy Council, which began during Trump’s first term, may hold the answer. Since then, she has played a key role in coordinating major health policies, including revisions to childhood-vaccine recommendations and food pyramid redesign. Her efforts have been praised by leaders within the West Wing and HHS, who see her as a crucial partner in implementing MAHA initiatives.

However, Overton’s detractors paint a very different picture. They accuse her of being a “controlled opposition,” someone who uses her position to slow down or water down radical changes. This charge is not new; some have long criticized Overton for her alleged reluctance to push through sweeping reforms.

As the battle over Overton’s role in Trump’s administration continues, it becomes clear that she has become a lightning rod for criticism within MAHA circles. But what does this say about the broader dynamics at play? Is Overton truly the roadblock to radical change that her detractors claim, or is she simply doing her job as a policy maker?

The answer may lie in the administration’s priorities themselves. Trump’s MAHA initiative was launched with great fanfare, promising sweeping changes to federal health policy. However, since then, progress has been slow, and many of the original promises have been watered down or delayed.

In this context, Overton’s influence becomes clearer. Rather than being a lone obstacle to reform, she may be seen as a representative of the incremental, pragmatic approach that has characterized Trump’s administration on health policy. By slowing down or modifying radical changes, Overton may be trying to ensure that policies are implemented in a way that is both effective and sustainable.

The Senate confirmation hearings for the next Food and Drug Administration commissioner will soon provide a new platform for Overton’s critics to air their grievances. Regardless of the outcome, one thing is certain: Dr. Heidi Overton has become an unlikely focal point in the ongoing struggle over Trump’s health agenda.